Sequenom (SQNM) says it's achieved positive results from a study of its RetnaGene AMD laboratory-developed test, which is designed to accurately predict the risk of disease progression of age-related macular degeneration. The announcement was made during its presentation today at the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. Shares +0.3% AH.
Sequenom (SQNM) says it's achieved positive results from a study of its RetnaGene AMD...
From other sites
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
at CNBC.com (Mar 15, 2013)
at CNBC.com (Apr 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs